Form D · Pharmaceuticals

Antios Therapeutics Inc.

Mendham, NJ · CIK 0001760428

Offering snapshot reported Nov 16, 2021 · SEC filing

Reported sold
$75M
Offering amount: $86M
Investors reported
35
Form D · investor count
Minimum accepted
$0
Reported outside-investor minimum
First sale
Nov 2, 2021
As reported in this filing

What changed?

Latest filing versus its linked predecessor, where available.

No comparable changes in the displayed metrics.

Filing history

Scroll to see all columns →

FiledFiling typeReported soldChange vs linked filingInvestorsSource
Nov 16, 2021Initial$74,999,993No comparison35SEC filing
Apr 19, 2021Initial$32,000,000No comparisonNot reportedSEC filing
Aug 17, 2020Initial$4,399,999No comparison9SEC filing
Dec 5, 2018Initial$14,999,999No comparison10SEC filing

Offering details

Securities
Equity
Exemptions
06b
Duration over one year
No
Business combination
No
Sales commissions
$0
Finders' fees
$0
Form D file number
021-421266

Source: Form D, filed Nov 16, 2021. Minimum accepted may differ from a standard advertised minimum.

Fund connections

No confirmed ADV fund connection is available for this issuer.

People & organizations

Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.

People and organizations reported in Form D filings
NameReported role
Tamra Adams Executive
David Canner Director
Henry Lin Chen Director
Abel De La Rosa Director
Craig Gordon Director
Patrick Higgins Director
Idean Marvasty Executive
Douglas Mayers Executive
Gregory Mayes Director, Executive
Scott Morenstein Director
Iyona Rajkomar Director
Benjamin Rovinski Director
Nicole Vitulio Director
Nicole Vitullo Director

Issuer details

Industry: Pharmaceuticals (See others in industry)

Address:
20 Horseshoe Bend Road
Mendham, NJ, 07945